| 000 | 01057 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513124534.0 | ||
| 264 | 0 | _c19970925 | |
| 008 | 199709s 0 0 eng d | ||
| 022 | _a0012-1797 | ||
| 024 | 7 |
_a10.2337/diab.46.2.s90 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorrobin, D F | |
| 245 | 0 | 0 |
_aEssential fatty acids in the management of impaired nerve function in diabetes. _h[electronic resource] |
| 260 |
_bDiabetes _cSep 1997 |
||
| 300 |
_aS90-3 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xblood |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDiabetic Neuropathies _xdrug therapy |
| 650 | 0 | 4 |
_aFatty Acids, Essential _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 |
_agamma-Linolenic Acid _xtherapeutic use |
| 773 | 0 |
_tDiabetes _gvol. 46 Suppl 2 _gp. S90-3 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/diab.46.2.s90 _zAvailable from publisher's website |
| 999 |
_c9264407 _d9264407 |
||